Plasma Ceramide Species Are Associated with Diabetes Risk in Participants of the Strong Heart Study

Abstract

Background Few studies have assessed the associations of ceramides and sphingomyelins (SMs) with diabetes in humans. Objective We assessed associations of 15 circulating ceramides and SM species with incident diabetes in 2 studies. Methods The analysis included 435 American-Indian participants from the Strong Heart Study (nested case-control design for analyses; mean age: 57 y; 34% male; median time until diabetes 4.3 y for cases) and 1902 participants from the Strong Heart Family Study (prospective design for analyses; mean age: 37 y; 39% male; median 12.5 y of follow-up). Sphingolipid species were measured using stored plasma samples by sequential LC and MS. Using logistic regression and parametric survival models within studies, and an inverse-variance-weighted meta-analysis across studies, we examined associations of 15 ceramides and SM species with incident diabetes. Results There were 446 cases of incident diabetes across the studies. Higher circulating concentrations of ceramides containing stearic acid (Cer-18), arachidic acid (Cer-20), and behenic acid (Cer-22) were each associated with a higher risk of diabetes. The RRs for incident diabetes per 1 SD of each log ceramide species (μM) were 1.22 (95% CI: 1.09, 1.37) for Cer-18, 1.18 (95% CI: 1.06, 1.31) for Cer-20, and 1.20 (95% CI: 1.08, 1.32) for Cer-22. Although the magnitude of the risk estimates for the association of ceramides containing lignoceric acid (Cer-24) with diabetes was similar to those for Cer-18, Cer-20, and Cer-22 (RR = 1.13; 95% CI: 1.01, 1.26), the association was not statistically significant after correction for multiple testing (P = 0.007). Ceramides carrying palmitic acid (Cer-16), SMs, glucosyl-ceramides, or a lactosyl-ceramide were not associated with diabetes risk. Conclusions Higher concentrations of circulating Cer-18, Cer-20, and Cer-22 were associated with a higher risk of developing diabetes in 2 studies of American-Indian adults. This trial was registered at clinicaltrials.gov as NCT00005134.

Serum C18:1-Cer as a Potential Biomarker for Early Detection of Gestational Diabetes

“…Available data report an association between an increased risk of diabetes development and higher C18:0-Cer levels in plasma [31]. Similarly, in our experiment, in the GDM group this parameter increased during pregnancy and, in the second trimester, was revealed to be significantly higher than in the NGT group where it stayed at a constant level.…”

Plasma Sphingolipid Profile in Association with Incident Metabolic Syndrome in a Chinese Population-Based Cohort Study

“…Among the lipids of interest, several ceramides displayed significant positive associations with MetS incidence, which was in agreement with earlier prospective studies reporting that ceramide species including C18:0, C20:0, and C24:1 were positively associated with CVD [7,30] and T2D [12,31] in Western populations. Our study also extended these findings to include far more monounsaturated ceramide species (C20:1, C22:1).…”

Plasma epoxyeicosatrienoic acids and dihydroxyeicosatrieonic acids, insulin, glucose and risk of diabetes: The strong heart study

“…Among these, 310 of the samples from diabetes cases and 851 of the samples from non cases passed laboratory QC and had no missing values of key covariates (education and waist circumference) and comprised the analytical sample. In addition to the case-cohort sample, we also measured EETs and DHETs in 1993-1995 plasma samples from 271 participants from the original SHS cohort, without prevalent diabetes at the 1993-1995 exam, that had been randomly selected for a previous study [19] .…”